Public Profile: Formerly doing business as Arcaris, the firm was acquired by Deltagen in July 2001 and renamed Deltagen Proteomics. Deltagen Proteomics then ceased operations in early 2003 as part of a cost savings measure by the parent company. Arcaris had developed technologies consisting of genetic, proteomic and cell-biological systems for the identification and validation of drug targets and the creation of small molecule screens. Deltagen intended to use the information generated through these technologies to advance the discovery of new disease targets by defining the role of novel non-traditional targets within intracellular pathways with particular relevance to oncology, viral and infectious diseases. Additionally, the technologies developed by Arcaris were intended to facilitate the rapid development of small molecule screens against identified targets.